Drug Trial Radar · NCT05688475
A Rollover Study of CC-122
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Apr 11, 2023
Primary completion
Nov 30, 2026
Study completion Nov 30, 2026
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jan 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to provide CC-122 treatment to participants who have been receiving treatment in other CC-122 clinical trials investigating CC-122 for more than 5 years (CC-122-ST-001 \[NCT01421524\], CC-122-ST-002 \[NCT02509039\], CC-122-DBCL-001 \[NCT02031419\], and CC-122-NHL-001 \[NCT02417285\]), receiving clinical benefit from the treatment and to monitor the safety and tolerability of CC-122.
Conditions
- Non-Hodgkin Lymphoma
Interventions
CC-122Drug
Specified dose on specified days
DexamethasoneDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with serious adverse events (SAEs) for participants who received at least 1 dose of CC-122Time frame: Up to approximately 3 years
- Number of deaths for participants who received at least 1 dose of CC-122Time frame: Up to approximately 3 years
Locations
7 sites in 4 countries. Site status is shown where the registry gives one.
Local Institution - 100
New York, New York
Local Institution - 101
Nashville, Tennessee
Local Institution - 102
Madison, Wisconsin
Local Institution - 300
Bordeaux, France
Local Institution - 301
Marseille, France
Local Institution - 500
Koto-ku, Tokyo, Japan
Local Institution - 400
Amsterdam, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.